Clinical Trial Update: Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety and pharmacology of SNX-5422 Mesylate in subjects with refractory hematologic neoplasms has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Neoplasms

Drugs mentioned

• SNX-5422 Mesylate (SNX-5422 mesylate)

Snippet

Sponsor: Esanex Inc. | Conditions: Hematologic Neoplasms | Phase 1 | Status: COMPLETED